Patents by Inventor Kenneth M. Attie

Kenneth M. Attie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING ANEMIA
    Publication number: 20230142386
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate- 1 -risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Application
    Filed: September 14, 2022
    Publication date: May 11, 2023
    Applicant: Celgene Corporation
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
  • Methods for treating vascular eye disorders with ActRII antagonists
    Patent number: 11524990
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: December 13, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • Activin-ActRII antagonists and uses for treating anemia
    Patent number: 11471510
    Abstract: Provided herein are methods for the treatment in a subject of anemia, anemia requiring RBC transfusion, low or intermediate-1-risk myelodysplastic syndromes (MDS), and/or non-proliferative chronic myelomonocytic leukemia (CMML) in any mammals wherein the methods comprise administration of Activin-ActRII signaling inhibitors to a subject in need of the treatment.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 18, 2022
    Assignees: CELGENE CORPORATION, ACCELERON PHARMA INC.
    Inventors: Kenneth M. Attie, Christopher Rovaldi, Abderrahmane Laadem
  • METHODS AND COMPOSITIONS FOR TREATING ULCERS
    Publication number: 20220133853
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 5, 2022
    Inventor: Kenneth M. Attie
  • Methods and compositions for treating ulcers
    Patent number: 11260107
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: March 1, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventor: Kenneth M. Attie
  • TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS
    Publication number: 20210346464
    Abstract: Provided herein are methods for treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes in subjects with ring sideroblasts by subcutaneous administration of an ActRIIA or ActRIIB ligand trap.
    Type: Application
    Filed: October 30, 2019
    Publication date: November 11, 2021
    Inventors: Abderrahmane Laadem, Xianjuan Zhang, Kenneth M. Attie, Peter G. Linde
  • METHODS FOR TREATING MYELODYSPLASTIC SYNDROMES AND SIDEROBLASTIC ANEMIAS
    Publication number: 20210230239
    Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sideroblastic anemias and myelodysplastic syndromes or one or more complications associated sideroblastic anemias and myelodysplastic syndromes.
    Type: Application
    Filed: October 1, 2020
    Publication date: July 29, 2021
    Inventors: Kenneth M. Attie, Christopher Robert Rovaldi
  • ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF
    Publication number: 20210115105
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.
    Type: Application
    Filed: May 27, 2020
    Publication date: April 22, 2021
    Inventors: Jasbir Seehra, John Knopf, Kenneth M. Attie
  • Methods for treating myelodysplastic syndromes and sideroblastic anemias
    Patent number: 10829531
    Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sideroblastic anemias and myelodysplastic syndromes or one or more complications associated sideroblastic anemias and myelodysplastic syndromes.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 10, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Kenneth M. Attie, Christopher Robert Rovaldi
  • METHODS AND COMPOSITIONS FOR TREATING ULCERS
    Publication number: 20200109193
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 9, 2020
    Inventor: Kenneth M. Attie
  • METHODS FOR TREATING EYE DISORDERS
    Publication number: 20200071383
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Application
    Filed: April 10, 2019
    Publication date: March 5, 2020
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • Methods for treating vascular eye disorders with actrii antagonists
    Patent number: 10550170
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: February 4, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • Methods for treating ulcers in a hemoglobinopathy anemia with a soluble actRIIB polypeptide
    Patent number: 10487144
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: November 26, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventor: Kenneth M. Attie
  • METHODS FOR TREATING MYELODYSPLASTIC SYNDROMES AND SIDEROBLASTIC ANEMIAS
    Publication number: 20190233486
    Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sideroblastic anemias and myelodysplastic syndromes or one or more complications associated sideroblastic anemias and myelodysplastic syndromes.
    Type: Application
    Filed: December 5, 2018
    Publication date: August 1, 2019
    Inventors: Kenneth M. Attie, Christopher Robert Rovaldi
  • Methods for treating vascular eye disorders with actrii antagonists
    Patent number: 10301372
    Abstract: Disclosed herein are compositions and methods for increasing visual acuity in patients in need thereof and for treating vascular disorders of the eye.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: May 28, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Matthew L. Sherman, Kenneth M. Attie
  • Methods for treating myelodysplastic syndromes and sideroblastic anemias
    Patent number: 10189882
    Abstract: In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sideroblastic anemias and myelodysplastic syndromes or one or more complications associated sideroblastic anemias and myelodysplastic syndromes.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: January 29, 2019
    Assignee: ACCELERON PHARMA INC.
    Inventors: Kenneth M. Attie, Christopher Robert Rovaldi
  • METHODS AND COMPOSITIONS FOR TREATING ULCERS
    Publication number: 20180194834
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Application
    Filed: November 21, 2017
    Publication date: July 12, 2018
    Inventor: Kenneth M. Attie
  • ACTRIIB ANTAGONISTS AND DOSING AND USES THEREOF
    Publication number: 20180194828
    Abstract: In certain aspects, the present invention provides compositions and methods for promoting hone growth and increasing bone density, as well as for the treatment of multiple myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.
    Type: Application
    Filed: November 13, 2017
    Publication date: July 12, 2018
    Inventors: Jasbir Seehra, John Knopf, Kenneth M. Attie
  • TREATMENT OF BETA-THALASSEMIA USING ACTRII LIGAND TRAPS
    Publication number: 20180125928
    Abstract: Provided herein are methods of treating beta-thalassemia by subcutaneous administration of about 0.8 mg/kg of an ActRII signaling inhibitor. Also provided herein are methods of adjusting the dose of the ActRII signaling inhibitor administered to the subject.
    Type: Application
    Filed: May 12, 2016
    Publication date: May 10, 2018
    Applicants: CELGENE CORPORATION, ACCELERON PHARMA INC.
    Inventors: Kenneth M. Attie, Abderrahmane Laadem, Rajesh Chopra, Jay Backstrom
  • Methods for treating ulcers in thalassemia syndrome with an ActRIIB polypeptide
    Patent number: 9850298
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: December 26, 2017
    Assignee: ACCELERON PHARMA INC.
    Inventor: Kenneth M. Attie